{"log_id": 7773055974163083599, "direction": 0, "words_result_num": 40, "words_result": [{"probability": {"variance": 5e-06, "average": 0.998631, "min": 0.991416}, "location": {"width": 466, "top": 168, "height": 49, "left": 235}, "words": "未对儿童使用吉西他滨进行研究,因此儿童应慎用"}, {"probability": {"variance": 0, "average": 0.995402, "min": 0.995402}, "location": {"width": 29, "top": 163, "height": 27, "left": 1169}, "words": "品"}, {"probability": {"variance": 0.000158, "average": 0.997077, "min": 0.919922}, "location": {"width": 801, "top": 208, "height": 64, "left": 236}, "words": "65岁以上的老年患者耐受性未见明显变化,尽管年龄对吉西他滨的清除率和半衰期有影"}, {"probability": {"variance": 5e-06, "average": 0.995732, "min": 0.991539}, "location": {"width": 118, "top": 214, "height": 27, "left": 231}, "words": "【老年用药】"}, {"probability": {"variance": 0.055786, "average": 0.594104, "min": 0.357913}, "location": {"width": 48, "top": 202, "height": 27, "left": 1158}, "words": "品"}, {"probability": {"variance": 7e-05, "average": 0.995328, "min": 0.962058}, "location": {"width": 422, "top": 256, "height": 44, "left": 207}, "words": "响,但并没有证据表明高龄患者需要调整剂量"}, {"probability": {"variance": 0.00012, "average": 0.990885, "min": 0.969433}, "location": {"width": 160, "top": 293, "height": 35, "left": 236}, "words": "【药物相互作用】"}, {"probability": {"variance": 2e-06, "average": 0.998892, "min": 0.992387}, "location": {"width": 762, "top": 296, "height": 62, "left": 280}, "words": "吉西他滨与其他的抗肿瘤药物配伍进行联合或序贯化疗时,应考虑对骨髓抑制作用"}, {"probability": {"variance": 0, "average": 0.999428, "min": 0.998487}, "location": {"width": 66, "top": 371, "height": 25, "left": 211}, "words": "的蓄积"}, {"probability": {"variance": 1e-06, "average": 0.998288, "min": 0.997213}, "location": {"width": 41, "top": 407, "height": 23, "left": 285}, "words": "放疗"}, {"probability": {"variance": 0.000756, "average": 0.992536, "min": 0.830259}, "location": {"width": 761, "top": 409, "height": 60, "left": 284}, "words": "同步放化疗(放化疗一起应用或者不同治疗间的间隔≤7天)一与这种多途径治疗相"}, {"probability": {"variance": 0.000236, "average": 0.994933, "min": 0.90237}, "location": {"width": 829, "top": 446, "height": 64, "left": 216}, "words": "关的毒性取决于许多不同的因素,包括吉西他滨的剂量、吉西他滨的给药频率、放射治疗的"}, {"probability": {"variance": 6.4e-05, "average": 0.995994, "min": 0.961306}, "location": {"width": 834, "top": 484, "height": 62, "left": 213}, "words": "剂量、放疗采用的技术、靶组织和靶用量等等。临床前研究和临床研究显示,吉西他滨具有"}, {"probability": {"variance": 1.9e-05, "average": 0.996963, "min": 0.983021}, "location": {"width": 825, "top": 521, "height": 63, "left": 217}, "words": "放疗增敏作用。在一个单项研究中,非小细胞肺癌患者在连续6周内同时接受剂量为1,00"}, {"probability": {"variance": 2e-05, "average": 0.996907, "min": 0.984977}, "location": {"width": 832, "top": 558, "height": 65, "left": 217}, "words": "mg/m2的吉西他滨治疗和胸部治疗性放疗,研究中观察到患者出现严重的、具有潜在致命性"}, {"probability": {"variance": 4.9e-05, "average": 0.996757, "min": 0.960274}, "location": {"width": 825, "top": 596, "height": 64, "left": 219}, "words": "的粘膜炎,特别是食道炎和肺炎,正在接受大剂量放疗的患者尤其如此[中位治疗量4,79"}, {"probability": {"variance": 0.000748, "average": 0.989927, "min": 0.842667}, "location": {"width": 806, "top": 635, "height": 62, "left": 223}, "words": "m3]。此后进行的研究(如非小细胞肺癌II期研究)表明,在有着可预测毒性的情况下"}, {"probability": {"variance": 1.5e-05, "average": 0.997976, "min": 0.981632}, "location": {"width": 831, "top": 671, "height": 63, "left": 223}, "words": "在进行放疗的同时给予相对低剂量的吉西他滨治疗也是可行的。在6周的时间里同时给予"}, {"probability": {"variance": 0.005742, "average": 0.982189, "min": 0.48098}, "location": {"width": 789, "top": 711, "height": 60, "left": 223}, "words": "剂量为66Gy的胸部放疗、吉西他滨(600mg/m2,4次)和顺铂(80mg/m2,2次)治疗"}, {"probability": {"variance": 0.005727, "average": 0.978878, "min": 0.539684}, "location": {"width": 834, "top": 746, "height": 61, "left": 225}, "words": "些I期和II期研究显示,对非小细胞肺癌和胰腺癌可以同时给予放疗和剂量高达300mg/m2"}, {"probability": {"variance": 0.000385, "average": 0.993372, "min": 0.904244}, "location": {"width": 832, "top": 783, "height": 63, "left": 226}, "words": "周的吉西他滨单药治疗。对于所有的肿瘤类型,目前尚未确定出与治疗剂量放疗同时应用的"}, {"probability": {"variance": 2.4e-05, "average": 0.997187, "min": 0.983435}, "location": {"width": 276, "top": 844, "height": 38, "left": 227}, "words": "安全的最佳吉西他滨治疗方案"}, {"probability": {"variance": 0.005139, "average": 0.978984, "min": 0.589456}, "location": {"width": 761, "top": 896, "height": 59, "left": 303}, "words": "非同步放化疗(不同治疗间的时间间隔>7天)数据分析显示,在放疗前后7天以上的"}, {"probability": {"variance": 0.009403, "average": 0.974213, "min": 0.524256}, "location": {"width": 832, "top": 932, "height": 65, "left": 232}, "words": "时间里应用吉西他滨治疗,不会使毒性增加伯可能出现放射诚忆反应。研究资料显示,吉"}, {"probability": {"variance": 0.000123, "average": 0.995405, "min": 0.952373}, "location": {"width": 684, "top": 975, "height": 58, "left": 233}, "words": "西他滨治疗应在放疗急性反应好转以后或者放疗结束至少1周之后才能进行"}, {"probability": {"variance": 6.5e-05, "average": 0.995981, "min": 0.954181}, "location": {"width": 762, "top": 1046, "height": 58, "left": 307}, "words": "目前已有靶组织出现放射损伤的报告(如,食道炎、大肠炎和肺炎),这些损伤与患"}, {"probability": {"variance": 4.6e-05, "average": 0.996663, "min": 0.973991}, "location": {"width": 408, "top": 1100, "height": 45, "left": 235}, "words": "者放疗时同时或不同时应用的吉西他滨相关"}, {"probability": {"variance": 1.4e-05, "average": 0.99649, "min": 0.988987}, "location": {"width": 118, "top": 1184, "height": 28, "left": 268}, "words": "【药物过量】"}, {"probability": {"variance": 0.000725, "average": 0.992577, "min": 0.827959}, "location": {"width": 761, "top": 1188, "height": 59, "left": 311}, "words": "对吉西他滨过量尚无解毒剂。曾有报告单次静脉给药5.7g/m2,输注时间在30分钟"}, {"probability": {"variance": 2e-06, "average": 0.998856, "min": 0.995067}, "location": {"width": 832, "top": 1226, "height": 60, "left": 242}, "words": "以上,每两周一次,所产生的毒性反应是临床上可接受的。临床一旦怀疑有过量情况,应对"}, {"probability": {"variance": 1e-06, "average": 0.99893, "min": 0.995202}, "location": {"width": 530, "top": 1275, "height": 51, "left": 241}, "words": "血液学指标进行适当的监测,必要时对病人进行支持治疗"}, {"probability": {"variance": 1e-06, "average": 0.999219, "min": 0.996852}, "location": {"width": 119, "top": 1326, "height": 27, "left": 272}, "words": "【药理毒理】"}, {"probability": {"variance": 2.6e-05, "average": 0.996988, "min": 0.976725}, "location": {"width": 811, "top": 1354, "height": 59, "left": 267}, "words": "本品是细胞周期特异性抗代谢类抗癌药,主要杀伤DNA合成期(s期)细胞,也可以阻"}, {"probability": {"variance": 9e-06, "average": 0.996809, "min": 0.99178}, "location": {"width": 90, "top": 1355, "height": 28, "left": 266}, "words": "药理作用"}, {"probability": {"variance": 0.002839, "average": 0.982949, "min": 0.670807}, "location": {"width": 837, "top": 1382, "height": 60, "left": 244}, "words": "断细胞由GI期向S期进展。本品在细胞内经核苷激酶转化为具有活性的二磷酸盐( dfdcdp)"}, {"probability": {"variance": 0.001024, "average": 0.986829, "min": 0.868431}, "location": {"width": 833, "top": 1411, "height": 58, "left": 247}, "words": "和三磷酸盐( dfdctp),抑制DNA的合成。一方面, dfdcdp抑制核苷酸还原酶,使合成"}, {"probability": {"variance": 8.5e-05, "average": 0.994193, "min": 0.967868}, "location": {"width": 829, "top": 1439, "height": 57, "left": 253}, "words": "DNA必需的三磷酸脱氧核苷(包括dCTP在内)生成减少。另一方面, dfdctp与dCTP竞"}, {"probability": {"variance": 0.001803, "average": 0.981596, "min": 0.828135}, "location": {"width": 830, "top": 1467, "height": 56, "left": 249}, "words": "争掺入DNA分子中,而细胞内dCTP浓度的降低更加促进 dfdctp向DNA的掺入。 dfdctp"}, {"probability": {"variance": 0.012576, "average": 0.959729, "min": 0.448654}, "location": {"width": 832, "top": 1492, "height": 61, "left": 249}, "words": "摻入DNA后,由于DNA聚台酶不能去除掺入的 dfdctp而修复延伸中的DNA链,在延"}, {"probability": {"variance": 0.001496, "average": 0.984365, "min": 0.832238}, "location": {"width": 835, "top": 1523, "height": 56, "left": 249}, "words": "伸链中掺入的 dfdctp可进一步抑制DNA合成。本品可使CEM(慢性红系骨髓增生症)的"}], "language": 3}